

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 405/14, 405/12, 417/12, A61K 31/495	A1	(11) International Publication Number: WO 99/29687 (43) International Publication Date: 17 June 1999 (17.06.99)
--	----	--

(21) International Application Number: PCT/EP98/07771

(22) International Filing Date: 27 November 1998 (27.11.98)

(30) Priority Data:
97203808.7 5 December 1997 (05.12.97) EP

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WIGERINCK, Piet, Tom, Bert, Paul [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VERSCHUEREN, Wim, Gaston [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). SCHROVEN, Marc, Francis, Josephine [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). DE BRUYN, Marc, Frans, Leopold [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).



(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES HAVING FUNDIC RELAXATION PROPERTIES



(57) Abstract

The present invention of compounds of formula (I), a stereochemically isomeric form thereof, an *N*-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein Alk^1 is C_{1-6} alkanediyl optionally substituted with hydroxy, C_{1-6} alkyloxy or C_{1-6} alkylcarbonyloxy; $\text{Z}^1\text{-Z}^2$ is a bivalent radical; R^1 , R^2 and R^3 are each independently selected from hydrogen, C_{1-6} alkyl, hydroxy, halo and the like; or when R^1 and R^2 are on adjacent carbon atoms, R^1 and R^2 taken together may form a bivalent radical; R^4 is hydrogen or C_{1-6} alkyl; A is a bivalent radical of formula $\text{-NR}^6\text{-Alk}^2\text{-(b-1)}$, or $\text{-NpiperidinyI-(CH}_2\text{)}_m\text{-(b-2)}$ wherein m is 0 or 1; R^5 is a radical of formula (A), wherein n is 1 or 2; p^1 is 0, and p^2 is 1 or 2; or p^1 is 1 or 2, and p^2 is 0; X is oxygen, sulfur or =NR^9 ; Y is oxygen or sulfur; R^7 is hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, phenyl or phenylmethyl; R^8 is C_{1-6} alkyl, C_{3-6} cycloalkyl phenyl or phenylmethyl; R^9 is cyano, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} alkyloxycarbonyl or aminocarbonyl; R^{10} is hydrogen or C_{1-6} alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

(BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES
HAVING FUNDIC RELAXATION PROPERTIES


- 5 The present invention is concerned with novel aminomethylchromane compounds having fundic relaxation properties. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
- 10 Structurally related aminomethylchromane derivatives are disclosed in US-5,541,199 as selective autoreceptor agonists useful as antipsychotic agents. Other structurally related aminomethylchroman derivatives having affinity for cerebral 5-hydroxytryptamine receptors of the 5-HT₁ type and therefore suitable for the treatment of disorders of the central nervous system are disclosed in US-5,137,901.
- 15 EP-0,546,388, published on 16 June 1993, discloses structurally related aminomethylchroman derivatives having affinity for cerebral 5-hydroxytryptamine receptors of the 5-HT₁ type and for dopamine receptors of the D₂-type. EP-0,628,310, published on 14 December 1994, encompasses the use of the same aminomethylchroman
- 20 derivatives for the inhibition of HIV-protease.
- DE-2,400,094, published on 18 July 1974, discloses 1-[1-[2-(1,4-benzodioxan-2-yl)-2-hydroxyethyl]-4-piperidyl]-2-benzimidazolinones possessing blood pressure lowering activity.
- 25 WO-93/17017, published on 2 September 1993, discloses [(benzodioxane, benzofuran or benzopyran)alkylamino]alkyl-substituted guanidine as selective vasoconstrictors useful to treat conditions related to vasodilatation such as, e.g., migraine, cluster headache and headache associated with vascular disorders.
- 30 WO-95/05383, published on 23 February 1995, encompasses dihydrobenzopyran-pyrimidine derivatives also having vasoconstrictive activity.
- Other structurally related aminomethylchroman derivatives are disclosed in
- 35 WO-97/28157, published on 7 August 1997, as α_2 -adrenergic receptor antagonists useful in the treatment of degenerative neurological conditions.

The compounds of the present invention differ from the cited art-known compounds structurally, by the nature of the R⁵ substituent, and pharmacologically by the fact that,

unexpectedly, these compounds have fundic relaxation properties. Furthermore, the compounds of the present invention have additional beneficial pharmacological properties in that they have little or no vasoconstrictor activity.

- 5 During the consumption of a meal the fundus, *i.e.* the proximal part of the stomach, relaxes and provides a "reservoir" function. Patients having an impaired adaptive relaxation of the fundus upon food ingestion have been shown to be hypersensitive to gastric distension and display dyspeptic symptoms. Therefore, it is believed that compounds which are able to normalize an impaired fundic relaxation are useful to
- 10 relieve patients suffering from said dyspeptic symptoms.

The present invention concerns compounds of formula (I)



- 15 a stereochemically isomeric form thereof, an *N*-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein
- Alk^1 is C_{1-4} alkylcarbonyl, C_{1-4} alkylcarbonyl C_{1-4} alkyl, carbonyl, carbonyl C_{1-4} alkyl, or C_{1-6} alkanediyl optionally substituted with hydroxy, C_{1-4} alkyloxy, C_{1-4} alkylcarbonyloxy, C_{1-4} alkylcarbonyloxy C_{1-4} alkyloxy, or
- 20 C_{3-6} cycloalkylcarbonyloxy C_{1-4} alkyloxy, or


$-\text{Z}^1-\text{Z}^2-$ is a bivalent radical of formula

- | | | | |
|---|--------|---|--------|
| $-\text{CH}_2-$ | (e-1). | $-\text{CH}=\text{CH}-$ | (e-6), |
| $-\text{O}-\text{CH}_2-$ | (e-2). | $-\text{CH}_2-\text{CH}=\text{CH}-$ | (e-7), |
| $-\text{S}-\text{CH}_2-$ | (e-3). | $-\text{CH}_2-\text{CH}_2-\text{CH}=\text{CH}-$ | (e-8), |
| 25 $-\text{CH}_2-\text{CH}_2-$ | (e-4). | $-\text{CH}=\text{CH}-$ | (e-9); |
| $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ | (e-5). | | |

- R^1 , R^2 and R^3 are each independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} alkenyl, C_{1-6} alkyloxy, trihalomethyl, trihalomethoxy, halo, hydroxy, cyano, nitro, amino, C_{1-6} alkylcarbonylamino, C_{1-6} alkyloxy, C_{1-4} alkylcarbonyloxy, aminocarbonyl, mono- or di(C_{1-6} alkyl)aminocarbonyl, amino C_{1-6} alkyl, mono- or di(C_{1-6} alkyl)amino C_{1-6} alkyl, C_{1-4} alkylcarbonyloxy C_{1-4} alkyloxy, or C_{3-6} cycloalkylcarbonyloxy C_{1-4} alkyloxy; or
- 30 when R^1 and R^2 are on adjacent carbon atoms, R^1 and R^2 taken together may form a bivalent radical of formula

- 35 $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ (a-1), $-\text{O}-\text{CH}_2-\text{CH}_2-$ (a-6),



-3-



5 wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by hydroxy, C₁₋₄alkyl or CH₂OH;

R⁴ is hydrogen, C₁₋₆alkyl, or a direct bond when the bivalent radical -Z¹-Z²- is of formula (e-6), (e-7) or (e-8);

A is a bivalent radical of formula




10

wherein the nitrogen atom is connected to Alk¹ and, m is 0 or 1;

Alk² is C₁₋₆alkanediyl;

15 R⁶ is hydrogen, C₁₋₆alkyl, C₁₋₄alkylcarbonyl, C₁₋₄alkyloxycarbonyl, phenylmethyl, C₁₋₄alkylaminocarbonyl, C₁₋₄alkylcarbonyloxyC₁₋₄alkyloxycarbonyl, or C₃₋₆cycloalkylcarbonyloxyC₁₋₄alkyloxycarbonyloxy;

R⁵ is a radical of formula



20 wherein n is 1 or 2;

p¹ is 0, and p² is 1 or 2; or

p¹ is 1 or 2, and p² is 0;

X is oxygen, sulfur, NR⁹ or CHNO₂;

Y is oxygen or sulfur;


25 R⁷ is hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl or phenylmethyl;

R⁸ is C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl or phenylmethyl;

R⁹ is cyano, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkyloxycarbonyl or aminocarbonyl;

R¹⁰ is hydrogen or C₁₋₆alkyl; and

Q is a bivalent radical of formula




-4-

-CH₂-CH₂-CH₂-CH₂- (d-3),-CO-CH₂- (d-6),


wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by C₁₋₄alkyl, hydroxy or phenyl, or

Q is a bivalent radical of formula



(d-7)


, or




(d-8)

As used in the foregoing definitions halo is generic to fluoro, chloro, bromo and iodo; C₁₋₄alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methyl-ethyl, 2-methylpropyl and the like; C₁₋₆alkyl is meant to include C₁₋₄alkyl and the higher homologues thereof having 5 or 6 carbon atoms, such as, for example, 2-methyl-butyl, pentyl, hexyl and the like; C₃₋₆cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; C₃₋₆alkenyl defines straight and branched chain unsaturated hydrocarbon radicals having from 3 to 6 carbon atoms, such as propenyl, butenyl, pentenyl or hexenyl; C₁₋₂alkanediyl defines methylene or 1,2-ethanediyl; C₂₋₄alkanediyl defines bivalent straight or branched chain hydrocarbon radicals containing from 2 to 4 carbon atoms such as, for example, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, and the branched isomers thereof; C₁₋₅alkanediyl defines bivalent straight or branched chain hydrocarbon radicals containing from 1 to 5 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, and the branched isomers thereof; C₁₋₆alkanediyl includes C₁₋₅alkanediyl and the higher homologues thereof having 6 carbon atoms such as, for example, 1,6-hexanediyl and the like. The term "CO" refers to a carbonyl group.

Some examples of the R⁵ moiety are :



-5-



The term "stereochemically isomeric forms" as used hereinbefore defines all the possible isomeric forms which the compounds of formula (I) may possess. Unless
 5 otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration.

10 Compounds encompassing double bonds can have an E or Z-stereochemistry at said double bond. Stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be embraced within the scope of this invention.

The pharmaceutically acceptable acid addition salts as mentioned hereinabove are
 15 meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and
 20 the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (*i.e.* ethanedioic), malonic, succinic (*i.e.* butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

25 Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

The term addition salt as used hereinabove also comprises the solvates which the
 30 compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

The *N*-oxide forms of the compounds of formula (I), which may be prepared in art-known manners, are meant to comprise those compounds of formula (I) wherein the
 35 bivalent radical of formula A represents a radical of formula (b-I) wherein R⁶ is other

than hydrogen or the bivalent radical of formula A represents a radical of formula (b-2), wherein the nitrogen atom in the is oxidized to the *N*-oxide.

Interesting compounds are those compounds of formula (I) wherein one or more of the following restrictions apply :

- a) the bivalent radical $-Z^1-Z^2-$ is a radical of formula (e-4);
- b) R^1 , R^2 and R^3 are each independently selected from hydrogen, C_{1-6} alkyl, hydroxy or halo;
- c) R^4 is hydrogen; and/or
- d) Alk^1 is C_{1-2} alkanediyl optionally substituted with hydroxy, in particular Alk^1 is CH_2 .

A first group of particular compounds consists of those compounds of formula (I) wherein the bivalent radical A is of formula (b-1).

A second group of particular compounds consists of those compounds of formula (I) wherein the bivalent radical A is of formula (b-2).

Preferred compounds are those compounds of formula (I) wherein R^5 is a radical of formula (c-1) wherein X is oxygen, and Q is a radical of formula (d-1) or (d-2) wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by C_{1-4} alkyl.

More preferred compounds are those compounds of formula (I) wherein R^4 is hydrogen; A is a radical of formula (b-1) wherein R^6 is hydrogen or C_{1-6} alkyl, and Alk^2 is C_{2-4} alkanediyl; and R^5 is a radical of formula (c-1) wherein X is oxygen, R^7 is hydrogen, and Q is (d-2).

Other more preferred compounds are those compounds of formula (I) wherein R^4 is hydrogen, A is a radical of formula (b-2), and R^5 is a radical of formula (c-1) wherein X is oxygen, R^7 is hydrogen, and Q is (d-2).


Most preferred compounds are

- 1-[3-[[[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]amino]-propyl]-tetrahydro-2(1*H*)-pyrimidinone; a stereoisomeric form thereof or a pharmaceutically acceptable acid addition salt;
- (*R*)-1-[3-[[[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]amino]propyl]-tetrahydro-2(1*H*)-pyrimidinone; or a pharmaceutically acceptable acid addition salt thereof; and


-7-

(R)-1-[3-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]tetrahydro-2(1H)-pyrimidinone [R-(R*,R*)]-2,3-dihydroxybutanedioate.

- The compounds of the present invention can generally be prepared by alkylating an intermediate of formula (III) with an intermediate of formula (II), wherein W is an appropriate leaving group such as, for example, halo, e.g. fluoro, chloro, bromo, iodo, or in some instances W may also be a sulfonyloxy group, e.g. methanesulfonyloxy, benzenesulfonyloxy, trifluoromethanesulfonyloxy and the like reactive leaving groups. The reaction can be performed in a reaction-inert solvent such as, for example, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base such as, for example, sodium carbonate, potassium carbonate, calciumoxide or triethylamine. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried out at a temperature ranging between room temperature and the reflux temperature of the reaction mixture and, if desired, the reaction may be carried out in an autoclave at an increased pressure.




- Compounds of formula (I) can also be prepared by reductively alkylating an intermediate of formula (IV), wherein Alk¹ represents a direct bond or C₁₋₅alkanediyl, following art-known reductive alkylation procedures with an intermediate of formula (III).



- Said reductive alkylation can be performed in a reaction-inert solvent such as, for example, dichloromethane, ethanol, toluene or a mixture thereof, and in the presence of a reducing agent such as, for example, a borohydride, e.g. sodium borohydride, sodium cyanoborohydride or triacetoxy borohydride. It may also be convenient to use hydrogen as a reducing agent in combination with a suitable catalyst such as, for example, palladium-on-charcoal, rhodium-on-carbon or platinum-on-charcoal. In case hydrogen is used as reducing agent, it may be advantageous to add a dehydrating agent to the


reaction mixture such as, for example, aluminium *tert*-butoxide. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may also be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g., thiophene or quinoline-sulphur. To enhance the rate of the reaction, the temperature may be elevated in a range between room temperature and the reflux temperature of the reaction mixture and optionally the pressure of the hydrogen gas may be raised.

Alternatively, compounds of formula (I) can also be prepared by reacting an acid chloride of formula (V), wherein Alk^1 represents C_{1-5} alkanediyl or a direct bond, with an intermediate of formula (III) under suitable reaction conditions.




Said reaction can be performed under hydrogenation conditions with hydrogen gas in the presence of a suitable catalyst such as, for example, palladium-on-charcoal, rhodium-on-carbon or platinum-on-charcoal, in a suitable solvent such as, for example, ethyl acetate, and in the presence of magnesiumoxide. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may also be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g. thiophene or quinoline-sulphur. To enhance the rate of the reaction, the temperature may be elevated in a range between room temperature and the reflux temperature of the reaction mixture and optionally the pressure of the hydrogen gas may be raised.

Compounds of formula (I-a), defined as compounds of formula (I) wherein R^5 is a radical of formula (c-1) wherein R^7 is hydrogen, X^1 represents oxygen or sulfur and Q is a bivalent radical of formula (d-2), can be prepared by reacting an intermediate of formula (VI) with an intermediate of formula (VII) in a reaction-inert solvent such as, e.g. tetrahydrofuran and the like.



-9-



The compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions. For instance, compounds of formula (I) wherein R^6 is phenylmethyl can be converted to the corresponding compounds of formula (I) wherein R^6 is hydrogen by art-known debenzylation procedures. Said debenzylation can be performed following art-known procedures such as catalytic hydrogenation using appropriate catalysts, e.g. platinum on charcoal, palladium on charcoal, in appropriate solvents such as methanol, ethanol, 2-propanol, diethyl ether, tetrahydrofuran, and the like. Furthermore, compounds of formula (I) wherein R^6 is hydrogen may be alkylated using art-known procedures such as, e.g. reductive *N*-alkylation with a suitable aldehyde or ketone, or compounds of formula (I) wherein R^6 is hydrogen can be reacted with an acyl halide or an acid anhydride.

The compounds of formula (I) may also be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarbo-peroxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzene-carboperoxoic acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. *tert*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

The starting materials and some of the intermediates are known compounds and are commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example, a number of intermediates of formula (II), (VI) or (V) may be prepared according to art-known methodologies described in WO-93/17017 and WO-95/053837.

Compounds of formula (I) and some of the intermediates may have one or more stereogenic centers in their structure, present in a R or a S configuration, such as, e.g. the carbon atom bearing the R⁴ substituent, and the carbon atom linked to the -Alk¹-A-R⁵ moiety.

5

The compounds of formula (I) as prepared in the hereinabove described processes may be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

10
15
20

The compounds of formula (I), the *N*-oxide forms, the pharmaceutically acceptable salts and stereoisomeric forms thereof possess favourable fundic relaxation properties as evidenced in pharmacological example C-1, the "Gastric tone measured by an electronic barostat in conscious dogs"-test.

25

Furthermore, as demonstrated in pharmacological example C.2 "Vasoconstrictive activity on basilar artery", the compounds of the present invention have additional beneficial pharmacological properties in that they have little or no vasoconstrictor activity. Vasoconstrictor activity can cause undesirable side-effects such as coronary spasms which can induce chest pain.

30

In view of the capability of the compounds of the present invention to relax the fundus, the subject compounds are useful to treat conditions related to a hampered or impaired relaxation of the fundus such as, e.g. dyspepsia, early satiety, bloating and anorexia.

35

Dyspepsia is described as a motility disorder. Symptoms can be caused by a delayed gastric emptying or by impaired relaxation of the fundus to food ingestion. Warm-blooded animals, including humans, (generally called herein patients) suffering from

-11-

dyspeptic symptoms as a result of delayed gastric emptying usually have a normal fundic relaxation and can be relieved of their dyspeptic symptoms by administering a prokinetic agent such as, e.g. cisapride. Patients can have dyspeptic symptoms without having a disturbed gastric emptying. Their dyspeptic symptoms may result from a hypercontracted fundus or hypersensitivity resulting in a diminished compliance and abnormalities in the adaptive fundic relaxation. A hypercontracted fundus results in a diminished compliance of the stomach. The "compliance of the stomach" can be expressed as the ratio of the volume of the stomach over the pressure exerted by the stomach wall. The compliance of the stomach relates to the gastric tone, which is the result of the tonic contraction of muscle fibers of the proximal stomach. This proximal part of the stomach, by exerting a regulated tonic contraction (gastric tone), accomplishes the reservoir function of the stomach.

Patients suffering from early satiety cannot finish a normal meal since they feel saturated before they are able to finish said normal meal. Normally when a subject starts eating, the stomach will show an adaptive relaxation, *i.e.* the stomach will relax to accept the food that is ingested. This adaptive relaxation is not possible when the compliance of the stomach is hampered which results in an impaired relaxation of the fundus.

In view of the utility of the compounds of formula (I), it follows that the present invention also provides a method of treating warm-blooded animals, including humans, (generally called herein patients) suffering from impaired relaxation of the fundus to food ingestion. Consequently a method of treatment is provided for relieving patients suffering from conditions, such as, for example, dyspepsia, early satiety, bloating and anorexia.

Hence, the use of a compound of formula (I) as medicine is provided, and in particular the use of a compound of formula (I) for the manufacture of a medicine for treating conditions involving an impaired relaxation of the fundus to food ingestion. Both prophylactic and therapeutic treatment are envisaged.

The symptoms of impaired fundic relaxation may also arise due to the intake of chemical substances, e.g. Selective Serotonin Re-uptake Inhibitors (SSRI's), such as fluoxetine, paroxetine, fluvoxamine, citalopram and sertraline.

Another functional gastrointestinal disorder is irritable bowel syndrome whereby one of its features is believed to be related to hypersensitivity of the gut to distension. Hence it

is therefore believed that modulation of said hypersensitivity by the compounds of the present invention having fundus relaxation properties may result in a reduction of the symptoms in subjects suffering from IBS. Accordingly the use of a compound of formula (I) for the manufacture of a medicine for treating IBS (irritable bowel syndrome) is provided.

To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid addition salts of (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically

discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

For oral administration, the pharmaceutical compositions may take the form of solid dose forms, for example, tablets (both swallowable-only and chewable forms), capsules or gelcaps, prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art.

Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means, optionally with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, methylcellulose, hydroxypropyl methylcellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid).

Pharmaceutically acceptable sweeteners comprise preferably at least one intense sweetener such as saccharin, sodium or calcium saccharin, aspartame, acesulfame potassium, sodium cyclamate, alitame, a dihydrochalcone sweetener, monellin, stevioside or sucralose (4,1',6'-trichloro-4,1'.6'-trideoxygalactosucrose), preferably saccharin, sodium or calcium saccharin, and optionally a bulk sweetener such as sorbitol, mannitol, fructose, sucrose, maltose, isomalt, glucose, hydrogenated glucose syrup, xylitol, caramel or honey.

Intense sweeteners are conveniently employed in low concentrations. For example, in the case of sodium saccharin, the concentration may range from 0.04% to 0.1% (w/v) based on the total volume of the final formulation, and preferably is about 0.06% in the low-dosage formulations and about 0.08% in the high-dosage ones. The bulk sweetener

can effectively be used in larger quantities ranging from about 10% to about 35%, preferably from about 10% to 15% (w/v).

5 The pharmaceutically acceptable flavours which can mask the bitter tasting ingredients in the low-dosage formulations are preferably fruit flavours such as cherry, raspberry, black currant or strawberry flavour. A combination of two flavours may yield very good results. In the high-dosage formulations stronger flavours may be required such as Caramel Chocolate flavour, Mint Cool flavour, Fantasy flavour and the like pharmaceutically acceptable strong flavours. Each flavour may be present in the final
10 composition in a concentration ranging from 0.05% to 1% (w/v). Combinations of said strong flavours are advantageously used. Preferably a flavour is used that does not undergo any change or loss of taste and colour under the acidic conditions of the formulation.

15 The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly
20 soluble derivatives, for example as a sparingly soluble salt.

The compounds of the invention may be formulated for parenteral administration by injection, conveniently intravenous, intramuscular or subcutaneous injection, for example by bolus injection or continuous intravenous infusion. Formulations for
25 injection may be presented in unit dosage form e.g. in ampoules or in multidose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as isotonicizing, suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a
30 suitable vehicle, e.g. sterile pyrogen-free water before use.

The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
35

For intranasal administration the compounds of the invention may be used, for example, as a liquid spray, as a powder or in the form of drops.

The formulations of the present invention may optionally include an anti-flatulent, such as simethicone, alpha-D-galactosidase and the like.

- 5 In general it is contemplated that a therapeutically effective amount would be from about 0.001 mg/kg to about 2 mg/kg body weight, preferably from about 0.02 mg/kg to about 0.5 mg/kg body weight. A method of treatment may also include administering the active ingredient on a regimen of between two or four intakes per day.

Experimental part

- 10 In the procedures described hereinafter the following abbreviations were used: "ACN" stands for acetonitrile; "THF", which stands for tetrahydrofuran; "DCM" stands for dichloromethane; "DIPE" stands for diisopropylether; and "DMF" means *N,N*-dimethylformamide.
- 15 For some chemicals the chemical formula was used, e.g. H₂ for hydrogen gas, N₂ for nitrogen gas, CH₂Cl₂ for dichloromethane, CH₃OH for methanol, NH₃ for ammonia, HCl for hydrochloric acid, and NaOH for sodium hydroxide.

- 20 In those cases the stereochemically isomeric form which was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration.

A. Preparation of the intermediates

Example A.1

- 25 a) A solution of (+)-(R)- α -methylbenzylamine (0.37 mol) in ethanol (100 ml) was added to a solution of 3,4-dihydro-2*H*-1-benzopyran-2-carboxylic acid (0.36 mol) in ethanol (200 ml). The mixture was allowed to crystallize out. The precipitate was filtered off and dried. The residue was crystallized 4 times from ethanol. The precipitate was filtered off and dried. The residue was taken up in water, treated with HCl 10% and
- 30 extracted with diethyl ether. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 8.6 g of (-)-(R)-3,4-dihydro-2*H*-1-benzopyran-2-carboxylic acid (mp. 85.5°C, $[\alpha]_D^{20} = -6.7^\circ$ (c = 100 mg/10 ml in methanol)) (interm. 1).
- 35 b) Intermediate (1) (2.14 mol) was stirred in toluene (1280 ml) under an inert atmosphere. Ethanol (640 ml) and sulfuric acid (21 ml, 96%) were added at room temperature. The reaction mixture was stirred and refluxed for 3.5 hours under an inert atmosphere. The reaction mixture was cooled to room temperature. A solution of NaHCO₃ (68 g) in water (1900 ml) was added slowly and this mixture was stirred for 15 minutes. The organic layer was separated, dried, filtered and the filtrate was

- concentrated to a 600-ml volume. The concentrate, ethyl (-)-(R)-3,4-dihydro-2H-1-benzopyran-2-carboxylic ester, was used as such in next reaction step (interm. 2).
- c) A mixture of toluene (1000 ml) and ethanol (absolute, 520 ml) was stirred. Sodium borohydride (2.13 mol) was added at room temperature, under an inert atmosphere.
- 5 The mixture was heated to 50°C. Intermediate (2) (2.14 mol) was added dropwise at 50°C in a 90-minutes period (exothermic temperature rise of 15°C; cooling required). The reaction mixture was stirred for 90 minutes at 50°C. Water (1500 ml) was added while stirring. Then, 2-propanone (100 ml) was added dropwise under slight cooling. The mixture was decomposed with HCl (180 ml). The organic layer was separated.
- 10 dried, filtered and the solvent evaporated, yielding 295 g of (-)-(R)-3,4-dihydro-2H-1-benzopyran-2-methanol (interm. 3).
- d) A mixture of intermediate (3) (0.18 mol) in toluene (110 ml) and *N,N*-diethyl-ethanamine (29 ml) was stirred and cooled on an ice-bath. Methylsulfonyl chloride (0.20 mol) was added dropwise and the reaction mixture was stirred for 30 minutes at
- 15 room temperature. Water was added. The organic layer was separated, washed with water, dried, filtered and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried (vacuum), yielding 31.4g (72.0%) of (R)-3,4-dihydro-2H-1-benzopyran-2-methanol methanesulfonate (ester) (interm. 4).
- 20 Example A.2
- a) A mixture of (±)-3,4-dihydro-2H-benzopyran-2-carbonylchloride (0.5 mol) in *N,N*-dimethylacetamide (150 ml) and DIPE (350 ml) was hydrogenated with palladium on activated carbon (10%, 5.0 g) as a catalyst in the presence of a solution of thiophene in methanol (4%, 4 ml). After uptake of H₂ (1 equivalent), the catalyst was filtered off.
- 25 Potassium acetate (5 g) was added to the filtrate. Methanol (100 ml) was added, to give mixture (A). A mixture of [1-(phenylmethyl)-4-piperidiny]-carbamic acid 1,1-dimethylethyl ester (0.45 mol) in methanol (500 ml) was hydrogenated with palladium on activated carbon (10%, 5 g) as a catalyst. After uptake of hydrogen (1 eq.), the catalyst was filtered off and the filtrate was evaporated, to give residue (B). A mixture
- 30 of residue (B) in mixture (A) and methanol (100 ml) was hydrogenated with palladium on activated carbon (5 g) as a catalyst in the presence of a solution of thiophene in methanol (4%, 3 ml). After uptake of hydrogen (1 eq.), the catalyst was filtered off and the filtrate was evaporated. The residue was taken up into water, and extracted with diethyl ether. The separated organic layer was dried, filtered and the filtrate was treated
- 35 with activated charcoal, then filtered over dicalite, and the solvent was evaporated. The residue was crystallized from DIPE, filtered off and dried, yielding 64.4 g (41.8%) of product (fraction 1). Part (6.3 g) of this fraction was recrystallized from DIPE, filtered

off and dried, yielding 4.53 g of product. The filtrate was concentrated, stirred, and the resulting precipitate was filtered off and dried, yielding 35g (22.4%) of (\pm)-1,1-dimethylethyl [1-[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]-4-piperidinyl]carbamate (fraction 2) (interm. 5).

- 5 b) A mixture of intermediate (5) (fractions 1 + 2) in methanol (1300 ml) and a solution of hydrochloric acid in 2-propanol (400 ml) was stirred overnight at room temperature. The precipitate was filtered off and dried, yielding 72.4 g of product. Part of this fraction was dissolved in water, alkalized, and extracted with diethyl ether. The separated organic layer was dried, filtered and the solvent evaporated, yielding 36.9 g of
10 (\pm)-1-[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]-4-piperidinamine (interm. 6).
c) A mixture of intermediate (6) (0.047 mol) and acrylonitrile (0.047 mol) in ethanol (250 ml) was stirred and refluxed overnight. The solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/CH₃OH from 95/5 to
15 90/10). The desired fractions were collected and the solvent was evaporated. Toluene was added and azeotroped on the rotary evaporator, yielding 11.5g (81.9%) of (\pm)-3-[[1-[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]-4-piperidinyl]amino]propanenitrile (interm. 7).
d) A mixture of intermediate (7) (0.013 mol) in a solution of ammonia in methanol (200 ml) was hydrogenated with Raney nickel (3.0 g) as a catalyst. After uptake of hydrogen
20 (2 eq.), the catalyst was filtered off and the filtrate was evaporated, yielding 3.6g of (\pm)-*N*-[1-[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]-4-piperidinyl]-1,3-propanediamine (interm. 8).

Example A.3

- 25 a) A mixture of 1-[2-hydroxy-3-methyl-4-(phenylmethoxy)phenyl]-ethanone (0.098 mol) and ethanedioic acid, diethyl ester (0.11 mol) in toluene (100 ml) was added dropwise to a mixture of sodium methoxide (0.22 mol) in toluene (150 ml). The reaction mixture was stirred and refluxed for 2 hours. The solvent was evaporated. The residue was added to a mixture of acetic acid (150 ml) and hydrochloric acid (50 ml).
30 The reaction mixture was stirred and refluxed for 1 hour. The mixture was poured out onto ice. The resulting precipitate was filtered off and dried (vacuum; 70°C), yielding 29 g (95.4%) of 8-methyl-4-oxo-7-(phenylmethoxy)-4*H*-1-benzopyran-2-carboxylic acid (interm. 9).
b) A mixture of intermediate (9) (0.093 mol) and methanesulfonic acid (11 g) in
35 methanol (500 ml) was hydrogenated with palladium on activated carbon (3 g) as a catalyst. After uptake of H₂ (4 eq.), the catalyst was filtered off. The filtrate was evaporated. The residue was dissolved in DCM and the organic solution was washed

- with water, dried, filtered and the solvent was evaporated, yielding 19.2 g of (±)-methyl 3,4-dihydro-7-hydroxy-8-methyl-2*H*-1-benzopyran-2-carboxylate (interm. 10).
- c) Reaction under N₂ flow. A solution of diisobutylaluminum hydride in toluene (25%) was added dropwise to a mixture of intermediate (10) (0.077 mol) in toluene (250 ml) and THF (20 ml), stirred at -70°C. The reaction mixture was stirred for one hour at -70°C, then decomposed with methanol (35 ml). The reaction mixture was poured out into water and this mixture was acidified with hydrochloric acid. The organic layer was separated, and washed with water. The aqueous phase was extracted with DCM. The combined organic layers were dried, filtered and the solvent evaporated, yielding 13 g (87.8%) of (±)-3,4-dihydro-7-hydroxy-8-methyl-2*H*-1-benzopyran-2-carboxaldehyde (interm. 11).

Example A.4

- a) A mixture of *N*-[1-(phenylmethyl)-4-piperidinyl]-1,3-propanediamine (0.035 mol) and 2,2-dioxide 1,3,2-benzodioxathiole (0.035 mol) in 1,4-dioxane (250 ml) was stirred and refluxed overnight, then stirred for 2 days at 20°C. The solvent was evaporated. The residue was crystallized from ACN/H₂O. The precipitate was filtered off and dried, yielding 7.65 g of tetrahydro-2-[1-(phenylmethyl)-4-piperidinyl]-2*H*-1,2,6-thiadiazine, 1,1-dioxide (interm. 12).
- b) A mixture of intermediate (12) (0.021 mol) in methanol (150 ml) was hydrogenated with palladium on activated carbon (2.0 g) as a catalyst. After uptake of H₂ (1 eq.), the catalyst was filtered off and the filtrate was evaporated. The residue was crystallized from ACN. The precipitate was filtered off and dried, yielding 2.3 g (50.3%) of product. The filtrate was evaporated. Toluene was added and azeotroped on the rotary evaporator, yielding 1.4 g (30.6%) of tetrahydro-2-(4-piperidinyl)-2*H*-1,2,6-thiadiazine, 1,1-dioxide (interm. 13).

Example A.5

- a) A mixture of 1-(phenylmethyl)-4-piperidinemethanamine (0.076 mol) and acrylonitrile (0.076 mol) in ethanol (250 ml) was stirred and refluxed for 4 hours. The solvent was evaporated, yielding 20.0 g (102.4%, crude residue, used in next reaction step, without further purification) of 3-[[[1-(phenylmethyl)-4-piperidinyl]methyl]-amino]-propanenitrile (interm. 14).
- b) A mixture of intermediate (14) (0.078 mol) in a solution of ammonia in methanol (400 ml) was hydrogenated with Raney nickel (3 g) as a catalyst. After uptake of hydrogen (2 eq.), the catalyst was filtered off and the filtrate was evaporated, yielding

20.2 g (99.4%, used in next reaction step, without further purification) of *N*-[[1-(phenyl-methyl)-4-piperidinyl]methyl]-1,3-propanediamine (interm. 15).

- c) A mixture of intermediate (15) (0.027 mol) and 1,1'-carbonylbis-*1H*-imidazole (0.027 mol) was stirred and refluxed overnight. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent :
5 $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 93/7). The desired fractions were collected and the solvent was evaporated, yielding 2.9 g of product. Part of this fraction (0.5 g) was recrystallized from ACN, filtered off and dried, yielding 0.14 g of tetrahydro-1-[[1-(phenylmethyl)-4-piperidinyl]-methyl]-2(*1H*)-pyrimidinone (interm. 16).
- 10 d) A mixture of intermediate (16) (0.0084 mol) in methanol (150 ml) was hydrogenated with palladium on activated carbon (1g) as a catalyst. After uptake of H_2 (1 eq.), the catalyst was filtered off and the filtrate was evaporated, yielding 1.25g (75.9%) of tetrahydro-1-(4-piperidinylmethyl)-2(*1H*)-pyrimidinone (interm. 17).

15 B. Preparation of the final compounds

Example B.1

- A mixture of intermediate (4) (0.011 mol), 1-(3-aminopropyl)-tetrahydro-2(*1H*)pyrimidinone (0.011 mol) and calcium oxide (1 g) in THF (50 ml) was stirred overnight at 100°C (autoclave). The reaction mixture was filtered over dicalite and the
20 filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 95/5). The pure fractions were collected and the solvent was evaporated. The residue was dissolved in ethanol and converted into the ethanedioic acid salt (1:1). The precipitate was filtered off and dried (vacuum), yielding 2.2g (50.8%) of (R)-1-[3-[[3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]amino]propyl]-tetrahydro-2(*1H*)-pyrimidinone ethanedioate (1:1);
25 $[\alpha] = -54.56^\circ$ (c = 0.1 % in DMF) (comp. 3).

Example B.2

- A mixture of 3,4-dihydro-2*H*-1-benzopyran-2-carboxaldehyde (0.015 mol) and 1-(3-aminopropyl)tetrahydro-2(*1H*)-pyrimidinethione (0.01 mol) in methanol (150 ml) was
30 hydrogenated for 2 days at room temperature (atmospheric pressure) with palladium on activated carbon (2 g) as a catalyst. After uptake of H_2 (1 eq.), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 95/5). The pure
35 fractions were collected and the solvent was evaporated. The residue (0.3 g) was dissolved in ethanol (30 ml) and converted into the ethanedioic acid salt (1:1) with ethanedioic acid (0.3 g; 0.0124 mol). The precipitate was filtered off and dried

(vacuum), yielding 0.3 g (7%) of (\pm) -1-[3-[(3,4-dihydro-2*H*-1-benzopyran-2-yl)-methyl]amino]propyl]tetrahydro-2(1*H*)-pyrimidinethione ethanedioate(1:1); mp. 217.6°C (comp. 14).

5 Example B.3

A mixture of (-)-(R)-3,4-dihydro-2*H*-1-benzopyran-2-carbonyl chloride (0.2 mol) and magnesium oxide (40 g) in ethyl acetate (350 ml) was hydrogenated at 25°C with palladium on activated carbon (10 %) (5 g) as a catalyst in the presence of a solution (4%) of thiophene in methanol (5 ml). After uptake of H₂ (1 eq.), the catalyst was
10 filtered off and the filtrate was collected in a mixture of potassium acetate (7 g) in methanol (200 ml). A mixture of 1-(3-aminopropyl)-tetrahydro-2(1*H*)pyrimidinone (0.2 mol) in methanol (200 ml) was added and the mixture was hydrogenated (16 hours at 25°C; 16 hours at 50°C) with rhodium on activated carbon (5 %, 3 g) as a catalyst in the presence of a solution (4%) of thiophene in methanol (3 ml). After uptake of
15 hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was stirred in water, treated with 50% NaOH, and extracted with DCM. The separated organic layer was dried, filtered and the solvent evaporated. The residue was stood overnight in 2-propanone (500 ml). The supernatant was decanted off and the residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃)
20 95/5). The desired fractions were collected and their solvent was evaporated, yielding (R)-1-[3-[(3,4-dihydro-2*H*-1-benzopyran-2-yl)-methyl]amino]propyl]tetrahydro-2(1*H*)-pyrimidinone (comp. 2).

Example B.4

25 1,1'-Carbonylbis-1*H*-imidazole (0.02 mol) was added to a solution of (\pm) -*N*-(3-aminopropyl)-*N'*-[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]-*N'*-(phenylmethyl)-1,3-propanediamine (0.02 mol) in THF (100 ml). The reaction solution was stirred for 17 hours at room temperature. The solvent was evaporated. Water was added to the residue and the mixture was extracted with toluene. The organic layer was separated,
30 dried, filtered and the solvent evaporated. The residue was crystallized from ethyl acetate (50 ml). The precipitate was filtered off and dried, yielding 3.3 g (42%) of (\pm) -1-[3-[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl](phenylmethyl)amino]propyl]-tetrahydro-2(1*H*)-pyrimidinone (comp. 13); mp. 94.7°C

35 Example B.5

Cyanocarbonimidic acid diphenyl ester (0.01 mol) was added to a solution of (\pm) -*N*-(3-aminopropyl)-*N'*-[(3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]-1,3-propanediamine (0.01 mol) in DCM (100 ml), stirred at room temperature. The reaction mixture was

stirred for 17 hours at room temperature. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/(CH₃OH/NH₃) 95/5). The pure fractions were collected and the solvent was evaporated. The residue was dissolved in ethanol (50 ml) and converted into the ethanedioic acid salt (1:1) with ethanedioic acid (1.27 g; 0.01 mol). The precipitate was filtered off and dried (vacuum), yielding 2.5 g (59.9%) of (±)-1-[3-[[3,4-dihydro-2*H*-1-benzopyran-2-yl)-methyl]-amino]propyl]hexahydro-2-pyrimidinylidene]cyanamide ethanedioate(1:1) (comp. 21); mp. 177.5°C

10 Example B.6

A solution of compound (13) (0.009 mol) in methanol (150 ml) was hydrogenated at 50°C with palladium on activated carbon (2 g) as a catalyst. After uptake of H₂ (1 eq.), the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in ethanol (100 ml) and converted into the ethanedioic acid salt (1:1) with ethanedioic acid (1.16 g; 0.009 mol). The precipitate was filtered off and dried vacuum, yielding 2.8 g (79.1%) of (±)-1-[3-[[3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl]amino]-propyl]-tetrahydro-2(1*H*)-pyrimidinone ethanedioate(1:1) (comp. 1); mp. 226.3°C.

Example B.7

20 A mixture of compound (2) (0.0125 mol) and 2-propanone (0.017 mol) in methanol (150 ml) was hydrogenated at 50°C with palladium on activated carbon (2 g) as a catalyst in the presence of a solution (4%) of thiophene in methanol (2 ml). After uptake of H₂ (1 eq.), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/ (CH₃OH/NH₃) 94/5/1). The pure fractions were collected and the solvent was evaporated. The residue was dried, yielding 2.226 g of (R)-1-[3-[[3,4-dihydro-2*H*-1-benzopyran-2-yl)methyl](1-methylethylamino)propyl]tetrahydro-2(1*H*)-pyrimidinone (comp. 12).

30 Example B.8

A solution of (RR,SS)-3,4-dihydro-2-oxiranyl-2*H*-1-benzopyran (2.5 g) and 1-(4-piperidinyl)-2-imidazolidinone (2.4 g) in ethanol (70 ml) was stirred during 16 hours at reflux temperature. The reaction mixture was allowed to cool to room temperature and evaporated to dryness, yielding 3.7 g of (RR,SS)-1-[1-[2-(3,4-dihydro-2*H*-1-benzopyran-2-yl)-2-hydroxyethyl]-4-piperidinyl]-2-imidazolidinone (compound 20).

Example B.9

A mixture of N"-cyano-N-[1-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-4-piperidiny]-N'-(2,2-dimethoxyethyl)guanidine (0.0153 mol) and HCl (0.5 N, 46 ml) in THF (160 ml) was stirred and refluxed for 100 minutes. Ice-water was added. Na₂CO₃ was added portionwise to obtain a clear separation. The organic layer was separated, DCM was added, the whole was washed with water, dried, filtered and the solvent was evaporated. The residue was separated and purified by column chromatography over silica gel (separation first compound : eluent: CH₂Cl₂/CH₃OH 95/5; separation second compound : CH₂Cl₂/(CH₃OH/NH₃) 90/10). The two pure fraction groups were collected and their solvent was evaporated. Each residue was crystallized from ACN. Each precipitate was filtered off and dried, yielding 1.75 g [1-[1-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-4-piperidiny]-1H-imidazol-2-yl]cyanamide (compound 59) and 0.48 g (±)-[1-[1-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-4-piperidiny]-1H-imidazol-2-yl]urea (compound 66).

Example B.10

Compound (139) (0.0039 mol), BBr₃ (0.03 mol, 1 M in DCM, 30 ml) and DCM (50 ml) were mixed and cooled in an ice bath. The reaction mixture was stirred for 2 hours at 20°C. The mixture was decomposed with H₂O/NH₄OH (50/50; 100 ml) while cooling on an ice bath. The mixture was stirred for one hour. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was crystallized from ethanol. The precipitate was filtered off and dried, yielding 0.60 g (±)-(R*,S*)-1-[1-[2-(3,4-dihydro-8-hydroxy-2H-1-benzopyran-2-yl)-2-hydroxyethyl]-4-piperidiny]-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (compound 141).

Example B.11

A mixture of compound (150) (0.0028 mol) in methanol (100 ml) was hydrogenated with Pd/C (10%, 1.0 g) as a catalyst. After uptake of hydrogen (1 equivalent), the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in methanol/DIPE and converted into the ethanedioic acid salt (1:1). The precipitate was filtered off and dried, yielding 0.56 g (46.7%) of [R(R*,R*)]-1-[3-[[2-(3,4-dihydro-2H-1-benzopyran-2-yl)-2-hydroxyethyl]amino]propyl]-3,4,5,6-tetrahydro-2(1H)-pyrimidinone ethanedioate (1:1) (compound 145).


Example B.12

A mixture of compound (34) (0.0066 mol), Pd(OAc)₂ (0.050 g), 1,3-propanediyl-bis[diphenylphosphine] (DPPP) (0.200 g) and NH₃ (20 g; gas) in THF (100 ml) was stirred overnight at 150°C under carbon monoxide at a pressure of 0.51 10⁶ Pa (5 atm).

The reaction mixture was filtered and the filtrate was evaporated and purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 95/5). The pure fractions were collected and the solvent was evaporated, yielding (\pm)-2-[[[3-(hexahydro-2-oxo-1-pyrimidinyl)propyl](phenylmethyl)amino]methyl]-3,4-dihydro-2H-1-benzopyran-6-carboxamide (compound 51).

Example B.13

Triethylamine (0.01 mol) was added to compound (3) (0.0066 mol) in DCM (50 ml). Acetylchloride (0.0066 mol) was added and the reaction mixture was stirred for 24 hours at room temperature. The mixture was washed with water, then dried, filtered and the solvent was evaporated, yielding 1.91 g of ethyl (R)-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl][3-(hexahydro-2-oxo-1-pyrimidinyl)propyl]carbamate (compound 56).

The  moiety in the compounds of formula (I) is numbered as follows :






Table F-1 to F-8 list the compounds that were prepared according to one of the above Examples. The following abbreviations were used in the tables : $\text{C}_4\text{H}_6\text{O}_5$ stands for the 2-hydroxybutanedioic acid salt (malic acid salt), $\text{C}_2\text{H}_2\text{O}_4$ stands for the ethanedioate salt, $\text{C}_4\text{H}_6\text{O}_6$ stands for the [R-(R*,R*)]-2,3-dihydroxy-butanedioic acid salt (L-tartaric acid salt), (E)- $\text{C}_4\text{H}_4\text{O}_4$ stands for (E)-2-butenedioic acid salt (fumaric acid salt), (Z)- $\text{C}_4\text{H}_4\text{O}_4$ stands for (Z)-2-butenedioic acid salt (maleic acid salt), $\text{C}_2\text{H}_6\text{O}$ means ethanolate, $\text{C}_3\text{H}_8\text{O}$ stands for 2-propanolate, and C_6H_{11} stands for cyclohexyl.

Table F-1




Co No.	Ex. No.	R ¹	R ⁶	R ⁷	X	Physical data
1	B.6	H	H	H	O	$\text{C}_2\text{H}_2\text{O}_4$ (1:1); mp. 226.3°C

Co No.	Ex. No.	R ¹	R ⁶	R ⁷	X	Physical data
2	B.3	H	H	H	O	(R); $[\alpha]_D^{20} = -61.19^\circ$ (c=0.1 % in DMF)
3	B.1	H	H	H	O	(R); .C ₂ H ₂ O ₄ (1:1) $[\alpha]_D^{20} = -54.56^\circ$ (c = 0.1 % in DMF)
4	B.1	H	H	H	O	(R) (+)-[R-(R*,R*)]; .C ₄ H ₆ O ₆ (1:1).H ₂ O (1:1) $[\alpha]_D^{20} = -45.45^\circ$ (c = 0.1 % in CH ₃ OH)
5	B.1	H	H	H	S	(R); .C ₂ H ₂ O ₄ (1:1); mp. 216.9°C
6	B.1	H	H	H	O	(S); .C ₂ H ₂ O ₄ (1:1) $[\alpha]_D^{20} = +51.67^\circ$ (c=0.1 % in CH ₃ OH)
7	B.3	H	H	c.C ₆ H ₁₁	O	.C ₂ H ₂ O ₄ (1:1)
9	B.1	6-F	H	H	O	.C ₂ H ₂ O ₄ (1:1)
10	B.3	7-CH ₂ CH ₃	H	H	O	.C ₂ H ₂ O ₄ (1:1); mp. 208.3°C
11	B.1	H	-CH ₃	H	O	(R)
12	B.7	H	-CH(CH ₃) ₂	H	O	(R)
13	B.4	H	-CH ₂ C ₆ H ₅	H	O	mp. 94.7°C
14	B.2	H	H	H	S	(±); .C ₂ H ₂ O ₄ (1:1); mp. 217.6°C
28	B.3	H	H	H	O	(R); .(Z)-C ₄ H ₄ O ₄ (1:1)
29	B.3	H	H	H	O	(R); .(E)-C ₄ H ₄ O ₄ (1:1)
30	B.3	H	H	H	O	(R), .HCl (1:1)
31	B.3	H	H	H	O	.2HBr.H ₂ O
32	B.3	H	H	H	O	(R); .C ₄ H ₆ O ₅ (1:1) .H ₂ O (1:1)
33	B.1	6-Br	H	H	O	.C ₂ H ₂ O ₄ (1:1); mp. 220.9°C
34	B.1	6-Br	H	-CH ₂ C ₆ H ₅	O	-

Co No.	Ex. No.	R ¹	R ⁶	R ⁷	X	Physical data
35	B.1	6-CN	H	H	O	.C ₂ H ₂ O ₄ (1:1); mp. 226.3°C
36	B.1	7-C(CH ₃) ₃	H	H	O	.C ₂ H ₂ O ₄ (1:1); mp. 204.4°C
37	B.2	6-CH ₃	H	H	O	.C ₂ H ₂ O ₄ (1:1); mp. 215.4°C
38	B.1	6-COOC ₂ H ₅	H	H	O	.C ₂ H ₂ O ₄ (1:1); mp. 226.8°C
39	B.1	5-OCH ₃	H	H	O	.C ₂ H ₂ O ₄ (1:1)
40	B.1	5-OCH ₃	H	H	O	-
41	B.1	8-OCH ₃	H	H	O	.C ₂ H ₂ O ₄ (1:1); mp. 211.6°C
42	B.1	8-OCH ₃	H	H	O	-
43	B.1	7-OCH ₃	H	H	O	.C ₂ H ₂ O ₄ (1:1); mp. 218.3°C
44	B.1	7-OCH ₃	H	H	O	-
45	B.1	6-OCH ₃	H	H	O	.C ₂ H ₂ O ₄ (1:1)
46	B.1	6-OCH ₃	H	H	O	-
47	B.10	7-OH	H	H	O	.C ₂ H ₂ O ₄ (2:3); mp. 165.8°C
48	B.10	6-OH	H	H	O	.C ₂ H ₂ O ₄ (2:1) .C ₂ H ₆ O (1:1)
49	B.10	5-OH	H	H	O	.C ₂ H ₂ O ₄ (1:1); mp. 205.4°C
50	B.1	6-NHCOCH ₃	H	H	O	.C ₂ H ₂ O ₄ (1:1); mp. 215.7°C
51	B.12	6-CONH ₂	H	-CH ₂ C ₆ H ₅	O	-
52	B.11	6-CONH ₂	H	H	O	.C ₂ H ₂ O ₄ (1:1)
53	B.2	H	H	-C ₆ H ₅	O	.HCl (1:1); mp. 162.5°C
54	B.2	H	H	-CH ₂ C ₆ H ₅	O	.C ₂ H ₂ O ₄ (2:3); mp. 154.8°C

Co No.	Ex. No.	R ¹	R ⁶	R ⁷	X	Physical data
55	B.2	H	H	-CH(CH ₃) ₂	O	.C ₂ H ₂ O ₄ (1:1); mp. 178°C
56	B.13	H	H	-(CO)OCH ₂ CH ₃	O	(R)
57	B.13	H	H	-(CO)OC(CH ₃) ₃	O	(R)


Table F-2



5












Co No.	Ex. No.	R ⁴	R ⁷	=X	m	Q	Physical data
15	B.1	H	H	=O	0	-(CH ₂) ₂ -	mp. 144.2°C
16	B.4	H	H	=O	0	-(CH ₂) ₃ -	-
17	B.3	H	H	=O	0	-(CH ₂) ₃ -	(R); [α] _D ²⁰ = -73.81° (c=0.5 % in CH ₃ OH)
18	B.2	H	H	=O	1	-(CH ₂) ₃ -	(R)
58	B.8	CH ₃	H	=O	0	-(CH ₂) ₂ -	mp. 150.6°C
59	B.9	H	H	=NCN	0	-CH=CH-	-
60	B.2	H	H	=O	0	-CH ₂ CHOHCH ₂ -	mp. 147.7°C
61	B.2	H	H	=O	0	-CH ₂ C(CH ₃) ₂ CH ₂ -	-

Table F-3



10

Co No.	Ex. No.	R ¹	R ²	-Alk ¹ -A-R ⁵	Physical data
19	B.2	7-OH	8-CH ₃		.C ₂ H ₂ O ₄ (2:1) .H ₂ O(1:2)

Co No.	Ex. No.	R ¹	R ²	-Alk ¹ -A-R ⁵	Physical data
21	B.5	H	H		.C ₂ H ₂ O ₄ (1:1); mp. 177.5°C
22	B.2	H	H		(R)
23	B.5	H	H		-
24	B.2	H	H		[R,(A)]
25	B.2	H	H		[R,(B)]
62	B.1	H	H		mp. 152.5°C
63	B.1	H	H		mp. 135.2°C
64	B.8	H	H		(SS,RR); mp. 202.1°C
65	B.4	H	H		(±); .2H ₂ O.HCl
66	B.9	H	H		-
67	B.2	H	H		.HCl (1:1); mp. 166.9°C






















Co No.	Ex. No.	R ¹	R ²	-Alk ¹ -A-R ⁵	Physical data
68	B.2	5-CH ₃	7-CH ₃		.C ₂ H ₂ O ₄ (1:1)
69	B.1	H	H		(R)
8	B.1	H	H		(R); .C ₂ H ₂ O ₄ (1:1) [α] _D ²⁰ = -65.77° (c=0.1 % in DMF)
70	B.2	H	H		-
71	B.2	H	H		.HCl (1:1); mp. 223.9°C
72	B.2	H	H		.C ₂ H ₂ O ₄ (1:1); mp. 213.9°C
73	B.2	H	H		.HCl (1:1)











Table F-4



5

Co No.	Ex. No.	R ¹	-Alk ¹ -A-R ⁵	Physical data
26	B.1	H		mp. 181.0°C
27	B.1	H		mp. 187.8°C


Co No.	Ex. No.	R ¹	-Alk ¹ -A-R ⁵	Physical data
74	B.4	H		-
75	B.6	H		.HCl (1:1)
76	B.2	H		-
77	B.2	H		.HCl (1:1)
78	B.2	H		-
79	B.2	H		$[\alpha]_D^{20} = +23.35^\circ$, c = 4.8 mg/ml in CH ₃ OH
80	B.2	H		$[\alpha]_D^{20} = -21.29^\circ$, c = 5.1 mg/ml in CH ₃ OH
81	B.2	H		.C ₂ H ₂ O ₄ (2:3); mp. 149.2°C
82	B.2	H		.C ₂ H ₂ O ₄ (2:3)
83	B.2	H		mp. 127.9°C
84	B.2	H		.HCl (1:1); mp. 127.2°C

Co No.	Ex. No.	R ¹	-Alk ¹ -A-R ⁵	Physical data
85	B.2	H		-
86	B.2	H		mp. 204.8°C
87	B.2	H		mp. 234.1°C
88	B.2	H		.C ₂ H ₂ O ₄ (1:1)
89	B.2	H		.C ₂ H ₂ O ₄ (1:1)
90	B.2	7-OCH ₃		.C ₂ H ₂ O ₄ (1:1)
91	B.8	H		-
92	B.11	H		.C ₂ H ₂ O ₄ (1:1)
93	B.2	6-OCH ₃		.C ₂ H ₂ O ₄ (1:1)
94	B.2	H		.C ₂ H ₂ O ₄ (1:1)

-31-

Co No.	Ex. No.	R ¹	-Alk ¹ -A-R ⁵	Physical data
95	B.2	H		mp. 178°C
96	B.2	8-OCH ₃		.C ₂ H ₂ O ₄ (1:1)
97	B.2	H		.C ₂ H ₂ O ₄ (1:1)
98	B.2	7-OCH ₃		.C ₂ H ₂ O ₄ (1:1)
99	B.2	H		.C ₂ H ₂ O ₄ (1:1)
100	B.5	H		.C ₂ H ₂ O ₄ (1:1)

Table F-5



5

Co. No.	Ex. No.	-R ⁵	Physical data
101	B.1		mp. 183.5°C
102	B.1		mp. 174-174.8°C

-32-































Co. No.	Ex. No.	-R ⁵	Physical data
103	B.1		(A); mp. 171-172°C
104	B.1		(±); mp. 160 - 165°C
105	B.1		.HBr (1:1); mp. 260°C
106	B.1		mp. 157.3°C


















Table F-6












5

Co No.	Ex. No.	R ¹	R ⁴	R ⁷	A	Q	Physical data
20	B.8	H	H	H		-(CH ₂) ₂ -	(RR,SS); mp. 178.3°C
107	B.8	H	H	H			(SS,RR); mp. 214.4°C
108	B.8	H	H	H			(SR,RS); mp. 194.5°C
109	B.8	H	H	H		-(CH ₂) ₂ -	(RS,SR); mp. 193.7°C
110	B.8	H	H	-C ₆ H ₅		-(CH ₂) ₂ -	(RS,SR); mp. 172.2°C


Co No.	Ex. No.	R ¹	R ⁴	R ⁷	A	Q	Physical data
111	B.8	H	H	-C ₆ H ₅		-(CH ₂) ₂ -	(RS,SS); mp. 192.4°C
112	B.8	5-OCH ₃	H	H		-(CH ₂) ₂ -	(RS,SR); mp. 203.4°C
113	B.8	H	CH ₃	H		-(CH ₂) ₂ -	(A); mp. 175.7°C
114	B.8	H	H	H		-(CH ₂) ₂ -	(-)-(RS); mp. 150.2°C
115	B.8	H	H	H		-(CH ₂) ₂ -	(+)-(SR); mp. 158.2°C
116	B.8	6-F	H	H		-(CH ₂) ₂ -	(+)-(SR); mp. 169.6°C
117	B.8	H	H	H		-(CH ₂) ₃ -	(RS,SR); mp. 186.7°C
118	B.8	H	H	H		-(CH ₂) ₃ -	(RR,SS); mp. 195.7°C
119	B.8	6-Br	H	H		-(CH ₂) ₂ -	(SR,RS); mp. 180.3°C
120	B.8	6-Br	H	H		-(CH ₂) ₂ -	(SS,RR); mp. 183.0°C
121	B.8	6-F	H	H		-(CH ₂) ₂ -	(-); mp. 166.1°C
122	B.8	6-F	H	H		-(CH ₂) ₂ -	(+)-(SS); mp. 151.2°C
123	B.8	6-F	H	H		-(CH ₂) ₂ -	(-)-(RR); mp. 160.6°C
124	B.8	H	H	H			(RS,SR); mp. 203.4°C
125	B.8	H	H	H		-(CH ₂) ₂ -	(RS,SR); mp. 165.6°C
126	B.8	H	H	H		-(CH ₂) ₂ -	(RR,SS); mp. 168.3°C
127	B.8	H	H	H		-(CH ₂) ₃ -	(+)-(SR); mp. 189.6°C

Co No.	Ex. No.	R ¹	R ⁴	R ⁷	A	Q	Physical data
128	B.8	H	H	H		-(CH ₂) ₃ -	(-); mp. 184.2°C
129	B.8	8-OCH ₃	H	H		-(CH ₂) ₂ -	(RR,SS); mp. 142.6°C
130	B.8	8-OCH ₃	H	H		-(CH ₂) ₂ -	(RS,SR); mp. 164.1°C
131	B.8	8-OH	H	H		-(CH ₂) ₂ -	(RR,SS); mp. 194.6
132	B.8	8-OH	H	H		-(CH ₂) ₂ -	(SR,RS); mp. 184.3°C
133	B.8	H	H	H			(RR,SS); mp. 208.6°C
134	B.8	H	H	H			(RS,SR); mp. 236.4°C
135	B.8	H	H	H		-(CH ₂) ₂ -	(RR,SS); .HCl; mp. 179.9°C
136	B.8	H	H	H		-(CH ₂) ₂ -	(RS,SR); .HCl; mp. 186.8°C
137	B.8	H	H	H		-(CH ₂) ₄ -	(R*, S*); mp. 164.4°C
138	B.8	H	H	H		-(CH ₂) ₄ -	(R*,R*); mp. 155.8°C
139	B.8	8-OCH ₃	H	H		-(CH ₂) ₃ -	(R*, S*); .C ₃ H ₈ O (1:1)
140	B.8	8-OCH ₃	H	H		-(CH ₂) ₃ -	(R*,R*)
141	B.10	8-OH	H	H		-(CH ₂) ₃ -	(R*, S*)
142	B.10	8-OH	H	H		-(CH ₂) ₃ -	(R*,R*)
143	B.8	H	H	H	-NH(CH ₂) ₃ -	-(CH ₂) ₂ -	(RR,SS); mp. 83.2°C

Co No.	Ex. No.	R ¹	R ⁴	R ⁷	A	Q	Physical data
144	B.8	H	H	H	-NH(CH ₂) ₃ -	-(CH ₂) ₂ -	(SR,RS); .C ₂ H ₂ O ₄ ; mp. 157.9°C
145	B.11	H	H	H	-NH-(CH ₂) ₃ -	-(CH ₂) ₃ -	[R(R*,R*)]; .C ₂ H ₂ O ₄ (1:1); mp. 179.7°C
146	B.11	H	H	H	-NH-(CH ₂) ₃ -	-(CH ₂) ₃ -	[S(R*,R*)]; .C ₂ H ₂ O ₄ (1:1); mp. 181.8°C
147	B.11	H	H	H	-NH(CH ₂) ₃ -		(RR,SS); mp. 187.0°C
148	B.8	H	H	H			(RS,SR); mp. 157.5°C
149	B.8	H	H	H			(RR,SS)
150	B.8	H	H	H		-(CH ₂) ₃ -	[R(R*,R*)]
151	B.8	H	H	H		-(CH ₂) ₃ -	[S(R*,R*)]
152	B.8	H	H	H		-(CH ₂) ₃ -	[S(R*,R*)]
153	B.8	H	H	H		-(CH ₂) ₃ -	[R(R*,R*)]
154	B.11	H	H	H	-NH(CH ₂) ₂ -	-(CH ₂) ₃ -	[S(R*,R*)]
155	B.11	H	H	H	-NH(CH ₂) ₂ -	-(CH ₂) ₃ -	[R(R*,R*)]


(*) : attachment point to the nitrogen bearing the R⁷ group

Table F-7



Co. No.	Ex. No.		Physical data
156	B.2		mp. 190°C
157	B.2		
158	B.11		.C ₂ H ₂ O ₄ (1:1)
159	B.11		.C ₂ H ₂ O ₄ (1:1)
160	B.2		.C ₂ H ₂ O ₄ (1:1); mp. 194.8°C
161	B.2		.C ₂ H ₂ O ₄ (1:1)

5 Table F-8



Co. No.	Ex. No.	-R ^{1a} -R ^{2a} -	Alk ²	Q	Physical data
162	B.1	-(CH ₂) ₄ -	-(CH ₂) ₃ -	-(CH ₂) ₃ -	.C ₂ H ₂ O ₄ (1:1); mp. 228.8°C
163	B.1	-(CH ₂) ₄ -	-(CH ₂) ₃ -	-CH ₂ -C(CH ₃) ₃ -CH ₂ -	.C ₂ H ₂ O ₄ (1:1)
164	B.1	-CH=CH-CH=CH-	-(CH ₂) ₃ -	-(CH ₂) ₃ -	.C ₂ H ₂ O ₄ (1:1); mp. 228.8°C

C. Pharmacological examples

C.1. Gastric tone measured by an electronic barostat in conscious dogs

5 Gastric tone cannot be measured by manometric methods. Therefore an electronic barostat was used. This allows the study of the physiological pattern and regulation of gastric tone in conscious dogs and the influence of test-compounds on this tone.

10 The barostat consists of an air injection system which is connected by a double-lumen 14-French polyvinyl tube to an ultrathin flaccid polyethylene bag (maximal volume : ± 700 ml). Variations in gastric tone were measured by recording changes in the volume of air within an intragastric bag, maintained at a constant pressure, or at varying pressure levels. The barostat maintains a constant pressure (preselected) within a flaccid air-filled bag introduced into the stomach, changing the volume of air within the bag by an electronic feedback system.

15 Thus, the barostat measures gastric motor activity (contraction or relaxation) as changes in intragastric volume (decrease or increase resp.) at a constant intragastric pressure. The barostat consists of a strain gauge linked by an electronic relay to an air injection-aspiration system. Both the strain gauge and the injection system are connected by means of double-lumen polyvinyl tube to an ultrathin polyethylene bag. A dial in the barostat allows selection of the pressure level to be maintained within the intragastric bag.

25 Female beagle dogs, weighing 7-17 kg, were trained to stand quietly in Pavlov frames. They were implanted with a gastric cannula under general anaesthesia and aseptic precautions. After a median laparotomy, an incision was made through the gastric wall in longitudinal direction between the greater and the lesser curve, 2 cm above the nerves of Latarjet. The cannula was secured to the gastric wall by means of a double purse string suture and brought out via a stub wound at the left quadrant of the hypochondrium. Dogs were allowed a recovery period of two weeks.

30 At the beginning of the experiment, the cannula was opened in order to remove any gastric juice or food remnants. If necessary, the stomach was cleansed with 40 to 50 ml lukewarm water. The ultrathin bag of the barostat was positioned into the fundus of the stomach through the gastric cannula. In order to ensure easy unfolding of the intragastric bag during the experiment, a volume of 150-200 ml was injected into the bag by raising the pressure to maximally 14 mm Hg (about 1.87 kPa) very briefly. This procedure was repeated twice. A stabilisation period of 1 hour was allowed.

After a stabilization period of 30 minutes at an intragastric pressure of 2 mmHg (about 0.27 kPa), pressure-volume curves were constructed by increasing intragastric pressure with 2 mm Hg (0.27 kPa) steps (maximally 14 mm Hg (about 1.87 kPa)) (11 minutes at 2 mmHg (0.27 kPa) and 3 minutes at each pressure step). These changes in pressure could be set either manually or could be installed via a computer program (LabVIEW). At least 2 stable curves had to be observed before drug administration.

Then, the test compound was administered subcutaneously between the first 3-5 minutes at 2 mmHg (0.27 kPa). Test compounds were screened at 0.63 mg/kg s.c. Other doses and routes were tested if a test compound was shown to be active during the screening procedure. Four new pressure-volume curves were then constructed to evaluate the effect induced by the compound. Table C-1 summarizes the percentual effect on relaxation of the fundus, 1 hour after administration of the test compound.

Table C-1 :

Co. No.	% effect	Co. No.	% effect
1	23.0	17	34.9
3	36.2	20	9.5
6	7.3	23	3.6
8	14.0	24	16.1
9	16.7	26	19.4
13	0.4	27	21.9
15	12.5		


C.2 Vasoconstrictive activity on basilar artery

- Segments of basilar arteries taken from pigs (anaesthetised with sodium pentobarbital) were mounted for recording of isometric tension in organ baths. The preparations were bathed in Krebs - Henseleit solution. The solution was kept at 37°C and gassed with a mixture of 95% O₂ - 5% CO₂. The preparations were stretched until a stable basal tension of 2 grams was obtained.
- The preparations were made to constrict with serotonin (3×10^{-7} M). The response to the addition of serotonin was measured and subsequently the serotonin was washed away. This procedure was repeated until stable responses were obtained. Subsequently the test compound was administered to the organ bath and the constriction of the preparation was measured. This constrictive response was expressed as a percentage of the response to serotonin as measured previously.

The ED₅₀-value (molar concentration) is defined as the concentration at which a test compound causes 50% of the constrictive response obtained with serotonin. Said ED₅₀-values are estimated from experiments on three different preparations. A large number of compounds were tested. The following compounds had ED₅₀-values higher than 1.00x10⁻⁰⁶ M : 1, 3, 6, 9, 11, 13, 14, 17, 20, 23, 26, 38, 41, 43, 45, 47, 48, 50, 52, 53, 54, 55, 59, 60, 61, 64, 65, 66, 67, 72, 73, 75, 76, 79, 80, 83, 86, 87, 88, 89, 90, 92, 93, 95, 96, 109, 114, 115, 117, 118, 119, 121, 125, 127, 128, 129, 131, 133, 137, 138, 141, 143, 147, 148, 156, 164. Compound 10 had an ED₅₀-value of 1.13x10⁻⁰⁶ M, and compound 21 had an ED₅₀-value of 5.90x10⁻⁰⁷ M.

Claims

1. A compound of formula (I)



5 a stereochemically isomeric form thereof, an *N*-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein
 Alk¹ is C₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonylC₁₋₄alkyl, carbonyl, carbonylC₁₋₄alkyl, or C₁₋₆alkanediyl optionally substituted with hydroxy, C₁₋₄alkyloxy, C₁₋₄alkylcarbonyloxy, C₁₋₄alkylcarbonyloxyC₁₋₄alkyloxycarbonyloxy, or
 10 C₃₋₆cycloalkylcarbonyloxyC₁₋₄alkyloxycarbonyloxy;

-Z¹-Z²- is a bivalent radical of formula

-CH ₂ -	(e-1),	-CH=	(e-6),
-O-CH ₂ -	(e-2),	-CH ₂ -CH=	(e-7),
-S-CH ₂ -	(e-3),	-CH ₂ -CH ₂ -CH=	(e-8),
-CH ₂ -CH ₂ -	(e-4),	-CH=CH-	(e-9);
-CH ₂ -CH ₂ -CH ₂ -	(e-5),		

15 R¹, R² and R³ are each independently selected from hydrogen, C₁₋₆alkyl, C₃₋₆alkenyl, C₁₋₆alkyloxy, trihalomethyl, trihalomethoxy, halo, hydroxy, cyano, nitro, amino, C₁₋₆alkylcarbonylamino, C₁₋₆alkyloxycarbonyl, C₁₋₄alkylcarbonyloxy, aminocarbonyl, mono- or di(C₁₋₆alkyl)aminocarbonyl, aminoC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₄alkylcarbonyloxy-C₁₋₄alkyloxycarbonyloxy, or C₃₋₆cycloalkylcarbonyloxyC₁₋₄alkyloxy-carbonyloxy; or

25 when R¹ and R² are on adjacent carbon atoms, R¹ and R² taken together may form a bivalent radical of formula


-CH ₂ -CH ₂ -CH ₂ -	(a-1),	-O-CH ₂ -CH ₂ -	(a-6),
-CH ₂ -CH ₂ -CH ₂ -CH ₂ -	(a-2),	-O-CH ₂ -CH ₂ -O-	(a-7),
-CH ₂ -CH ₂ -CH ₂ -CH ₂ -CH ₂ -	(a-3),	-O-CH ₂ -CH ₂ -CH ₂ -	(a-8),
-CH=CH-CH=CH-	(a-4),	-O-CH ₂ -CH ₂ -CH ₂ -CH ₂ -	(a-9),
-O-CH ₂ -O-	(a-5),		

wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by hydroxy, C₁₋₄alkyl or CH₂OH;


35 R⁴ is hydrogen, C₁₋₆alkyl, or a direct bond when the bivalent radical -Z¹-Z²- is of formula (e-6), (e-7) or (e-8);

A is a bivalent radical of formula

-41-



(b-1)








(b-2)

wherein the nitrogen atom is connected to Alk¹ and,
m is 0 or 1;

Alk² is C₁₋₆alkanediyl;

- 5 R⁶ is hydrogen, C₁₋₆alkyl, C₁₋₄alkylcarbonyl, C₁₋₄alkyloxycarbonyl, phenylmethyl, C₁₋₄alkylaminocarbonyl, C₁₋₄alkylcarbonyloxy-C₁₋₄alkyloxycarbonyl, or C₃₋₆cycloalkylcarbonyloxyC₁₋₄alkyloxycarbonyloxy;
R⁵ is a radical of formula



10

wherein n is 1 or 2;

p¹ is 0, and p² is 1 or 2; or

p¹ is 1 or 2, and p² is 0;

X is oxygen, sulfur, NR⁹ or CHNO₂;

- 15 Y is oxygen or sulfur;






R⁷ is hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl or phenylmethyl;

R⁸ is C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl or phenylmethyl;

R⁹ is cyano, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkyloxycarbonyl or aminocarbonyl;

R¹⁰ is hydrogen or C₁₋₆alkyl; and


- 20 Q is a bivalent radical of formula



wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by C₁₋₄alkyl, hydroxy or phenyl, or


25

Q is a bivalent radical of formula




(d-7)

, or




(d-8)

2. A compound as claimed in claim 1 wherein the bivalent radical A is of formula (b-1).
- 5 3. A compound as claimed in claim 1 wherein the bivalent radical A is of formula (b-2).
4. A compound according to claim 1 wherein R⁴ is hydrogen; A is a radical of formula (b-1) wherein R⁶ is hydrogen or C₁₋₆alkyl, and Alk² is C₂₋₄alkanediyl; or A is a radical of formula (b-2); and R⁵ is a radical of formula (c-1) wherein X is oxygen, R⁷ is hydrogen, and Q is (d-1) or (d-2) wherein optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by C₁₋₄alkyl.
- 10 5. A compound according to claim 1 wherein the compound is 1-[3-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-propyl]-tetrahydro-2(1H)-pyrimidinone; a stereoisomeric form or a pharmaceutically acceptable acid addition salt thereof.
- 15 6. A compound according to claim 5 wherein the compound is (R)-1-[3-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]tetrahydro-2(1H)-pyrimidinone [R-(R*,R*)]-2,3-dihydroxybutanedioate.
- 20 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed in any of claims 1 to 6.
- 25 8. A process for preparing a pharmaceutical composition as claimed in claim 7 wherein a therapeutically active amount of a compound as claimed in any of claims 1 to 6 is intimately mixed with a pharmaceutically acceptable carrier.
- 30 9. A compound as claimed in any of claims 1 to 6 for use as a medicine.
10. A process for preparing a compound of formula (I) wherein
 - a) an intermediate of formula (II) is alkylated with an intermediate of formula (III) in a reaction-inert solvent and, optionally in the presence of a suitable base,




-43-

- b) an intermediate of formula (IV), wherein Alk^{1'} represents a direct bond or C₁₋₅alkanediyl, is reductively alkylated with an intermediate of formula (III);



5

- c) an intermediate of formula (V), wherein Alk^{1'} represents a direct bond or C₁₋₅alkanediyl, is reacted with an intermediate of formula (III);



10

wherein in the above reaction schemes the radicals A, R¹, R², R³, R⁴ and R⁵ are as defined in claim 1 and W is an appropriate leaving group;

- d) or, compounds of formula (I) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (I) is converted into an acid addition salt, or conversely, an acid addition salt of a compound of formula (I) is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

15

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/07771

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D405/14 C07D405/12 C07D417/12 A61K31/495

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 28 52 945 A (BOEHRINGER) 26 June 1980 see page 1 - page 12 ---	1-4, 7-10
X	EP 0 004 358 A (CIBA) 3 October 1979 see page 1 - page 9; examples 1-15 ---	1, 3, 4, 7-10
X	EP 0 048 218 A (CIBA) 24 March 1982 see claims; examples 1, 2 ---	1, 3, 4, 7-10
A	WO 97 28157 A (PIERRE FABRE) 7 August 1997 cited in the application see the whole document ---	1, 3, 4, 7-10
A	US 5 541 199 A (R.E. MEWSHAW) 30 July 1996 cited in the application see column 1 - column 8; example 3D ---	1, 2, 4, 7-10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 May 1999

Date of mailing of the international search report

25/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/07771

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 93 17017 A (JANSSEN) 2 September 1993 cited in the application see claims; tables 1,2 -----</p>	<p>1,2,4. 7-10</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/07771

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 2852945	A	26-06-1980	NONE	
EP 04358	A	03-10-1979	AR 227272 A	15-10-1982
			AR 231638 A	31-01-1985
			AR 227400 A	29-10-1982
			AR 227527 A	15-11-1982
			AT 372088 B	25-08-1983
			AT 352382 A	15-08-1985
			AT 352582 A	15-08-1985
			AU 529838 B	23-06-1983
			AU 4524379 A	27-09-1979
			DD 142341 A	18-06-1980
			DK 113079 A	21-09-1979
			FI 790894 A,B	21-09-1979
			GB 2019837 A,B	07-11-1979
			GR 71865 A	07-07-1983
			IE 48258 B	14-11-1984
			JP 54157570 A	12-12-1979
			NZ 189939 A	15-12-1981
			PT 69369 A	01-04-1979
			ZA 7900417 A	30-01-1980
			ZA 7901276 A	26-03-1980
EP 48218	A	24-03-1982	US 4329348 A	11-05-1982
			AU 7516881 A	18-03-1982
			DD 202292 A	07-09-1983
			DK 405981 A	13-03-1982
			FI 812811 A	13-03-1982
			GB 2083813 A	31-03-1982
			JP 57081483 A	21-05-1982
			PT 73657 A,B	01-10-1981
			ZA 8106322 A	29-09-1982
WO 9728157	A	07-08-1997	FR 2744451 A	08-08-1997
			AU 1606197 A	22-08-1997
US 5541199	A	30-07-1996	NONE	
WO 9317017	A	02-09-1993	AP 416 A	29-09-1995
			AT 138064 T	15-06-1996
			AU 3499193 A	13-09-1993
			BG 98870 A	31-03-1995
			CA 2117483 A	02-09-1993
			CN 1079470 A,B	15-12-1993
			CZ 9402020 A	18-01-1995
			DE 69302687 D	20-06-1996
			DE 69302687 T	14-11-1996
			DK 639192 T	19-08-1996
			EP 0639192 A	22-02-1995
			ES 2087721 T	16-07-1996
			FI 943928 A	26-08-1994
			GR 3019927 T	31-08-1996
			HR 930235 A	31-10-1997
			HU 71129 A	28-11-1995
			HU 9500317 A	28-09-1995
			IL 104868 A	04-01-1998
			JP 2779268 B	23-07-1998
			JP 7504408 T	18-05-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/07771

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9317017 A		LT 3049 B	25-10-1994
		LV 10715 A	20-06-1995
		LV 10715 B	20-12-1995
		MX 9301053 A	31-03-1994
		NO 943186 A	29-08-1994
		NZ 249124 A	28-08-1995
		PL 174736 B	30-09-1998
		SG 47763 A	17-04-1998
		SK 102994 A	11-07-1995
		US 5541180 A	30-07-1996
		US 5624952 A	29-04-1997
		US 5607949 A	04-03-1997
		US 5688952 A	18-11-1997
		ZA 9301404 A	26-08-1994

THIS PAGE BLANK (USPTO)